The combination of hormonal treatment based on a long-acting delivery system for the agonist [6-D- 
culated to release a controlled dose of 25 ,.g/day were injected intramuscularly once a month. Novantrone (0.25 mg/kg) was injected intravenously once every 3 weeks. Three separate experiments were carried out. When the therapy was started 45 days after transplantation and continued for 70 days, tumor volume in the presence of the microcapsules (966 ± 219 mm3) or Novantrone (3606 ± 785 mm3) given alone was significantly decreased compared to controls (14, 476 ± 3045 mm3). However, the combination of microcapsules and Novantrone caused a greater inhibition of tumor growth (189 ± 31 mm3) than the single agents. Similar effects were seen when the percent increase in tumor volume was examined. Tumor volume increased 10,527 ± 1803% for the control group. The inhibition of growth caused by the [D-Trp6JLH-RH microcapsules alone (672 ± 153% increase in volume) was again greater than that caused by Novantrone alone (2722 ± 421% increase). The combination of the two agents was again the most effective, resulting in an increase in tumor volume of only 105 ± 29%. Control tumors weighed 30.0 ± 6.5 g. Tumor weights were much less in the groups treated with either microcapsules (3.28 ± 0.69 g) or Novantrone (19. We have recently developed long-acting delivery systems for the 6-D-tryptophan analog of luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) based on microcapsule formulation of this analog in the biodegradable polymer poly(DLlactide-co-glycolide) (1) . Once-a-month intramuscular administration of microcapsules of [D-Trp6]LH-RH to rats bearing androgen-dependent Dunning R3327H prostate adenocarcinoma markedly inhibited tumor growth and suppressed testosterone serum levels more effectively than daily subcutaneous injections of equivalent, or larger, doses of unencapsulated analog (1) . The clinical therapeutic efficacy of these long-acting microcapsule preparations in patients with prostate cancer was also recently established by Roger et al. (2) and Parmar et al. (3) . This approach, which makes the treatment more convenient and efficacious as compared with daily administration and ensures patient compliance, could become the method of choice for the endocrine treatment of advanced prostate carcinoma. Nevertheless, the duration of remissions may be limited, as hormonal manipulations do not prevent the ultimate growth of hormoneindependent cells (4) (5) (6) (7) (8) (9) .
It has been demonstrated that carcinomas of the prostate are heterogeneous and contain both hormone-dependent and hormone-independent cells (1, 7, 10) . After androgen deprivation, most of the hormone-dependent cells stop proliferating and die, but hormone-independent cells originally present in the tumor, by a clonal selection process, eventually repopulate the tumor (7, 9) . As the prostate cancer progresses to a hormone-independent state, it becomes unresponsive to androgen-deprivation therapy (7) . Chemotherapy inhibits the proliferation of androgen-independent cells. It is thus possible that the use of a combination of chemotherapeutic and hormonal approaches would prevent or delay a condition whereby hormone-insensitive cells present in the originally endocrine-dependent tumor become the predominant component (4) (5) (6) (7) (8) (9) (10) (11) (12) .
In this study we used Novantrone (mitoxantrone dihydrochloride) (13) (14) (15) (16) , which is a modem synthetic chemotherapeutic agent with a putative mode of action similar to that of the anthracycline antibiotic Adriamycin but which is considerably less toxic. Novantrone was selected on the basis of its activity in a wide range of experimental animal tumors and its inhibitory effects on both proliferating and nonproliferating tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. cells (13) (14) (15) (16) disposable syringes in 0.7 ml of injection vehicle containing 2% CM-cellulose and 1% Tween 20 in water. This suspension was thoroughly mixed and injected through an 18-gauge needle deep into the thigh muscle of rats (1, 18) . The administration was repeated at monthly intervals. The rats (9-12 per group) were divided into four groups. Group 1, the control, was injected with vehicle only and group 2, with the microcapsules. Group 3 received Novantrone and group 4 was treated with a combination of microcapsules and Novantrone.
After the treatment period, the rats were sacrificed by decapitation. Trunk blood was collected and serum was separated for further analysis. Tumors and various organs were removed, cleaned, and carefully weighed. Serum concentrations of luteinizing hormone (LH), prolactin, and testosterone were measured by using radioimmunoassays as previously described (1, 18, 19) . All data are described as the mean ± SEM. Statistical analyses were performed by using a computer program and Duncan's new multiple-range test (20) (Fig. 1) . Similar results were obtained in experiment 1, in which the tumors grew at the same rate, and in experiment 2, in which the tumors showed a slower growth than in experiment 3, the untreated controls reaching a volume of 7306 ± 3976 mm3. The effects of the administration of the two agents on the percent change in tumor volume during the period of the experiment are shown in Fig. 2 . As measured by this parameter, the inhibition induced by the [D-Trp6]LH-RH microcapsules (672 ± 153% compared to the control of 10,527 ± 1803%; P < 0.01 vs. control) was again much greater than that of Novantrone (2722 ± 421%; P < 0.01 vs. control). The combination of the two agents (105 ± 29%; P < 0.01 vs. control) was again clearly the most effective and resulted in the greatest inhibition of the percent increase in tumor volume (Fig. 2) (Table 2) .
Every tumor was examined histologically. All tumors were well-differentiated adenocarcinomas (Fig. 3 Left) , but in the groups treated with microcapsules and combination of microcapsules and Novantrone, the number of the cells decreased and the glandular structures (of adenocarcinomas) showed considerable atrophic signs as compared to the control group (Fig. 3 Right) . In the group treated with Novantrone alone, fewer alterations occurred. A very important finding is the increase of the connective tissue in the group treated with the combination of microcapsules and Novantrone (Fig. 3 (2, 3, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . The therapy based on agonists of LH-RH avoids the cardiovascular and mammotropic side effects of estrogens and the psychological impact of orchiectomy (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . It has been suggested that treatment with [D-Trp6]LH-RH produces a higher rate of response than transcapsular orchiectomy (35) . The use of LH-RH agonists may be the method of choice for the treatment ofprostate cancer (3, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) been used successfully for the treatment of women with endometriosis (37) and children with precocious puberty (38) . However, the duration of response and the median survival time in patients with prostate cancer cannot yet be estimated.
It is well established for other hormonal methods of treatment that, in most patients with prostate cancer, the duration of remission may be limited and a relapse eventually occurs (5) (6) (7) (8) (9) (10) (11) . Recently, one patient relapsed after 18 months of objective and subjective remission in response to [DTrp6]LH-RH treatment, in spite of continued blockade of pituitary-gonadal axis, and had to be treated by chemotherapy with cyclophosphamide (34) . This relapse is attributed to a selective proliferation of clones of androgen-independent cancer cells that preexisted within the heterogeneous prostate tumor (7) (8) (9) . While hormone-dependent tumor cells stop growing after androgen ablation, the testosterone-insensitive cells are able to proliferate and eventually become predominant, although they may have represented initially only a small fraction of the starting tumor (7, 9) . The response rates in advanced prostatic carcinoma that are obtained with chemotherapy alone are generally low (10, 11) . The aim of combining hormonal therapy with chemotherapy is to prevent the proliferation of both hormone-dependent and hormone-independent cells. The use of both approaches, endocrine and chemotherapeutic, may increase the rate of response and its duration (5) (6) (7) (8) (9) (10) (11) 35) .
Previous study from this laboratory in rats bearing Dunning R3327H prostate tumors (1) has shown that when the combination therapy with microcapsules of [D-Trp6]LH-RH and the alkylating agent cyclophosphamide was initiated early in the progression of tumor development, then tumor growth was inhibited more effectively than when single agents were used (12) .
In the present experiments on the evaluation of the combination of hormonal therapy based on [D-Trp6]LH-RH with chemotherapy in prostate cancer we have used Novantrone (mitoxantrone dihydrochloride), an anthracenedione with some structural similarities to Adriamycin but without an amino-sugar moiety (13) (14) (15) (16) . Novantrone was reported to have equal or superior antitumor efficacy as compared to Adriamycin but reduced or no cardiotoxicity (13) . Adriamycin binds to DNA and inhibits RNA and DNA synthesis. Studies at the cellular level have shown that Novantrone has inhibitory effects on both proliferating (dividing) and nonproliferating (nondividing) cells (14, 15) . Thus, the cellkilling ability of this drug is not cell-cycle specific. Novantrone has a wide spectrum of activity against experimental murine tumors and shows synergism with cisplatin, cyclophosphamide, and other antineoplastic agents in colon and mammary adenocarcinoma. Novantrone was reported to induce a significant response in patients with breast cancer (16) . Since Adriamycin produces an objective response rate of about 25% in patients with metastatic prostate carcinoma, and Novantrone is much less toxic than Adriamycin, we have decided to evaluate its effect in the Dunning model ofprostate adenocarcinoma.
Chemotherapy is generally used in patients with advanced prostate cancer after they have become unresponsive to hormonal treatment (5, 6, 11 treatment based on microcapsules of the LH-RH agonist and chemotherapy could be superior to either modality alone, since a single approach affects only a portion of the tumor population (7) .
The timing of such combined therapy may be of great importance, as suggested by studies in experimental rat models (7) and in patients (5, 6) . Various findings reported previously indicate that combined therapy should be initiated soon after diagnosis is established (5, 12) . In addition, the response of cancer cells to chemotherapy might be potentiated by an early and transitory increase in testosterone levels after initial administration of LH-RH agonists. Thus, a hormonal treatment could stimulate cell division, recruit the cells into the cycle, partially synchronize the phase of cell growth, and significantly enhance the cells' sensitivity to some cytostatics. The fibroblastic proliferation observed in the histological study may indicate a favorable response to the therapy. Consequently, our present view is that combined therapy should be initiated, with chemotherapy being given several hours after the first administration of LH-RH agonists (35) .
The present results demonstrate the effectiveness of hormonal treatment based on microcapsules of [D-Trp6]LH-RH combined with Novantrone chemotherapy in suppressing the growth of Dunning R3327H prostate tumors in rats. Our results suggest that the combination of Novantrone with microcapsules of [D-Trp6]LH-RH might lead to a better therapeutic response than the treatment with LH-RH analog alone in patients with prostate carcinoma.
